MICHAEL KELLY

Corporate Board Profile

Tech Score: 0/100

FALCONSTOR SOFTWARE INC

Filing Date	Source Excerpt
2016-03-18	Michael P. Kelly has served as a director ... Mr. Kelly has been a director of the Company since October 2014. ... The Audit Committee consists of Messrs. Fischer (Chair), Kelly, Lieber and Rubenstein. ... The table below sets forth the compensation received by our non-employee directors for the year 2015. ... Michael Kelly $29,500 Fees Earned or Paid in Cash, $15,400 Stock Awards, Total $44,900.

NEOGENOMICS INC

Filing Date	Source Excerpt
2023-04-07	Michael Kelly, age 66, Board Member and Chair of the Audit and Finance Committee. Mr. Kelly has served as a director since July 2020. The Board currently has four standing committees: the Audit and Finance Committee, the Compliance Committee, the Culture and Compensation Committee, and the Nominating and Corporate Governance Committee. Michael Kelly serves as Chair of the Audit and Finance Committee. The following table provides the compensation of each of our independent directors for the year ended December 31, 2022. Mr. Kelly received total compensation of $269,002.
2024-04-08	Mr. Kelly has served as a director since July 2020 and served as the Board’s Lead Independent Director for the duration of Ms. Tetrault’s service as Executive Chair of the Board and Interim Chief Executive Officer in 2022. Mr. Kelly is a former senior executive of Amgen, Inc. ("Amgen") and is currently acting as Founder & President of Sentry Hill Partners, LLC, a global life sciences transformation and management consulting business he founded in 2018. Mr. Kelly has more than two decades of executive experience as a senior leader in the life sciences industry serving in various strategic finance and operations positions at Amgen from 2003 to 2017, most recently as Senior Vice President, Global Business Services and Vice President & CFO, International Commercial Operations. Mr. Kelly has also held positions at Biogen, Tanox, and Monsanto Life Sciences. Mr. Kelly currently serves as a director for Amicus Therapeutics, DMC Global, Inc., and Prime Medicine, Inc. Mr. Kelly serves on the Council of Advisors and was the former audit committee chair for Direct Relief, a humanitarian aid organization focused on health outcomes and disaster relief. Mr. Kelly holds a BS in business administration from Florida A&M University, concentrating in Finance and Industrial Relations. For service as a director during 2023, independent directors received total annual equity compensation having a grant date fair value of $240,000. For service as a director during 2023, each independent director received annual compensation of $50,000. Directors serving as Audit and Finance Committee members received annual compensation of $10,000. Directors serving as Culture and Compensation Committee members received annual compensation of $7,500.

Filing Date

Source Excerpt

2023-04-07

Michael Kelly, age 66, Board Member and Chair of the Audit and Finance Committee. Mr. Kelly has served as a director since July 2020. The Board currently has four standing committees: the Audit and Finance Committee, the Compliance Committee, the Culture and Compensation Committee, and the Nominating and Corporate Governance Committee. Michael Kelly serves as Chair of the Audit and Finance Committee. The following table provides the compensation of each of our independent directors for the year ended December 31, 2022. Mr. Kelly received total compensation of $269,002.

2024-04-08

Mr. Kelly has served as a director since July 2020 and served as the Board’s Lead Independent Director for the duration of Ms. Tetrault’s service as Executive Chair of the Board and Interim Chief Executive Officer in 2022. Mr. Kelly is a former senior executive of Amgen, Inc. ("Amgen") and is currently acting as Founder & President of Sentry Hill Partners, LLC, a global life sciences transformation and management consulting business he founded in 2018. Mr. Kelly has more than two decades of executive experience as a senior leader in the life sciences industry serving in various strategic finance and operations positions at Amgen from 2003 to 2017, most recently as Senior Vice President, Global Business Services and Vice President & CFO, International Commercial Operations. Mr. Kelly has also held positions at Biogen, Tanox, and Monsanto Life Sciences. Mr. Kelly currently serves as a director for Amicus Therapeutics, DMC Global, Inc., and Prime Medicine, Inc. Mr. Kelly serves on the Council of Advisors and was the former audit committee chair for Direct Relief, a humanitarian aid organization focused on health outcomes and disaster relief. Mr. Kelly holds a BS in business administration from Florida A&M University, concentrating in Finance and Industrial Relations. For service as a director during 2023, independent directors received total annual equity compensation having a grant date fair value of $240,000. For service as a director during 2023, each independent director received annual compensation of $50,000. Directors serving as Audit and Finance Committee members received annual compensation of $10,000. Directors serving as Culture and Compensation Committee members received annual compensation of $7,500.

NORTHERN OIL & GAS, INC.

Filing Date	Source Excerpt
2020-07-08	Michael Kelly

Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22